| Literature DB >> 26818610 |
Bu-Yeo Kim1, Hee Jin2, Yoon-Jin Lee3, Ga-Young Kang4, Jaeho Cho5, Yun-Sil Lee6.
Abstract
BACKGROUND: Despite the emergence of stereotactic body radiotherapy (SBRT) for treatment of medically inoperable early-stage non-small-cell lung cancer patients, the molecular effects of focal exposure of limited lung volumes to high-dose radiation have not been fully characterized. This study was designed to identify molecular changes induced by focal high-dose irradiation using a mouse model of SBRT.Entities:
Mesh:
Year: 2016 PMID: 26818610 PMCID: PMC4729165 DOI: 10.1186/s12863-016-0338-9
Source DB: PubMed Journal: BMC Genet ISSN: 1471-2156 Impact factor: 2.797
Fig. 1Fibrotic changes in the control or irradiated lung tissues after focal 90 Gy or 20 Gy irradiation. Mice were sacrificed at the indicated time points after irradiation, and the lungs were immersed in fixation solution. a Representative images of hematoxylin–eosin-stained lung sections from three mice are shown at each time point. The arrows indicate the focally irradiated area. b Lung sections were stained with Masson’s Trichrome stain to visualize blue-colored collagen deposition and quantitative assessments of the degree of collagen deposition were determined using an image J program (*p <0.05 vs non-irradiated control)
Fig. 2Temporal gene expression profile induced by radiation in mouse lung. Approximately 6,500 differentially expressed genes with a fold ratio greater than two or less than 0.5 (for up- and down-regulation, respectively) compared to the control in at least one sample were clustered hierarchically. Up-cluster and Down-cluster indicate the two sub-clusters. Columns and rows represent individual samples and genes, respectively. The expression ratio color scale ranges from red (high) to green (low), as indicated by the scale bar with log 2 units
Fig. 3Temporal gene expression patterns by focal exposure to high-dose radiation. Temporally altered genes were identified by the Short Time-series Expression Miner (STEM) analysis in (a) focally-irradiated regions and (b) non-irradiated neighboring lung regions. Genes were classified into three patterns (FDR <0.001) in both lung regions. Pattern 1, Pattern 2, and Pattern 3 comprised 4609, 676, and 64 genes, respectively, in (a) focally irradiated regions, and 4893, 218, and 27, respectively, in (b) non-irradiated neighboring lung regions. (c) The number of common genes between the two lung regions was compared according to the three patterns
Top 10 GO terms significantly enriched (FDR < 0.01) in lung focally exposed to high-dose radiation of 90 Gy
| Focally irradiated area | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Pattern 1 | Pattern 2 | Pattern 3 | |||||||||
| GO ID | Name |
| FDRa | ID | Name |
| FDR | ID | Name |
| FDR |
| GO:0016337 | Cell-cell adhesion | 7.33E-10 | 2.67E-06 | GO:0006955 | Immune response | 2.64E-63 | 5.58E-60 | GO:0007050 | Cell cycle arrest | 4.29E-07 | 2.24E-04 |
| GO:0007507 | Heart development | 9.75E-10 | 1.77E-06 | GO:0006952 | Defense response | 4.26E-30 | 4.50E-27 | GO:0022402 | Cell cycle process | 7.63E-07 | 2.52E-04 |
| GO:0007155 | Cell adhesion | 3.99E-09 | 4.85E-06 | GO:0006954 | Inflammatory response | 1.16E-26 | 8.20E-24 | GO:0008219 | Cell death | 5.86E-06 | 9.93E-04 |
| GO:0022610 | Biological adhesion | 3.99E-09 | 4.85E-06 | GO:0009611 | Response to wounding | 4.72E-26 | 2.49E-23 | GO:0016265 | Death | 6.77E-06 | 1.14E-03 |
| GO:0006355 | Regulation of transcription, DNA-dependent | 1.48E-08 | 1.35E-05 | GO:0002684 | Positive regulation of immune system process | 6.73E-21 | 2.84E-18 | GO:0006915 | Apoptosis | 2.68E-05 | 2.49E-03 |
| GO:0008016 | Regulation of heart contraction | 2.56E-08 | 1.87E-05 | GO:0001775 | Cell activation | 7.44E-18 | 2.62E-15 | GO:0007049 | Cell cycle | 2.79E-05 | 2.72E-03 |
| GO:0007156 | Homophilic cell adhesion | 3.02E-08 | 1.83E-05 | GO:0050778 | Positive regulation of immune response | 1.01E-17 | 3.05E-15 | GO:0012501 | Programmed cell death | 2.98E-05 | 3.13E-03 |
| GO:0051252 | Regulation of RNA metabolic process | 3.65E-08 | 1.90E-05 | GO:0002252 | Immune effector process | 1.52E-17 | 4.01E-15 | ||||
| GO:0048562 | Embryonic organ morphogenesis | 9.21E-08 | 4.19E-05 | GO:0045321 | Leukocyte activation | 2.21E-16 | 5.22E-14 | ||||
| GO:0007389 | Pattern specification process | 2.20E-07 | 8.89E-05 | GO:0048584 | Positive regulation of response to stimulus | 2.88E-15 | 6.10E-13 | ||||
| Neighboring area | |||||||||||
| Pattern 1 | Pattern 2 | Pattern 3 | |||||||||
| ID | Name |
| FDR | ID | Name |
| FDR | ID | Name |
| FDR |
| GO:0006355 | Regulation of transcription, DNA-dependent | 4.16E-08 | 1.56E-04 | GO:0006955 | Immune response | 2.00E-33 | 2.16E-30 | NA | NA | NA | NA |
| GO:0051252 | Regulation of RNA metabolic process | 1.03E-07 | 1.94E-04 | GO:0006954 | Inflammatory response | 2.39E-14 | 1.29E-11 | ||||
| GO:0006952 | Defense response | 1.23E-13 | 4.42E-11 | ||||||||
| GO:0009611 | Response to wounding | 1.63E-11 | 4.40E-09 | ||||||||
| GO:0042330 | Taxis | 2.75E-08 | 5.94E-06 | ||||||||
| GO:0006935 | Chemotaxis | 2.75E-08 | 5.94E-06 | ||||||||
| GO:0009615 | Response to virus | 9.79E-06 | 1.75E-03 | ||||||||
| GO:0002526 | Acute inflammatory response | 2.03E-05 | 3.12E-03 | ||||||||
| GO:0007626 | Locomotory behavior | 4.72E-05 | 6.34E-03 | ||||||||
| GO:0002684 | Positive regulation of immune system process | 6.48E-05 | 7.74E-03 | ||||||||
aFDR corrections were calculated using the Benjamini-Hochberg procedure
*p-values were calculated using Fischer’s test
Fig. 4Altered GO terms by focal exposure to high-dose radiation. The network structure among non-redundant GO terms was constructed from all enriched GO terms (FDR <0.01) using the REIVGO program in (a) focally-irradiated regions and (b) non-irradiated neighboring lung regions. The node size and color intensity are proportional to the hierarchical status and statistical significance of each node, respectively. The edge thickness between nodes represents the closeness of the two nodes. c Significantly enriched non-redundant GO terms at each time point were temporally distributed. The columns represent individual samples, while the rows represent statistically significant GO terms (FDR <0.01). The positions of the organ development-related terms and immune-related terms are indicated as bars. A full list of GO terms is depicted in Additional file 6
Pathways enriched in lung focally exposed to high-dose radiation of 90 Gy
| Focally irradiated area | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Pattern 1 | Pattern 2 | Pattern 3 | |||||||||
| KEGG ID | Name |
| FDRa | ID | Name |
| FDR | ID | Name |
| FDR |
| mmu05414 | Dilated cardiomyopathy | 3.31E-09 | 6.08E-07 | mmu04060 | Cytokine-cytokine receptor interaction | 5.25E-17 | 6.78E-15 | mmu04115 | p53 signaling pathway | 4.94E-09 | 1.78E-07 |
| mmu05410 | Hypertrophic cardiomyopathy | 1.75E-07 | 1.61E-05 | mmu05322 | Systemic lupus erythematosus | 2.32E-10 | 1.50E-08 | ||||
| mmu05412 | Arrhythmogenic right ventricular cardiomyopathy | 5.71E-06 | 3.50E-04 | mmu05332 | Graft-versus-host disease | 1.34E-09 | 5.78E-08 | ||||
| mmu04020 | Calcium signaling pathway | 1.24E-05 | 5.71E-04 | mmu05330 | Allograft rejection | 1.81E-09 | 5.83E-08 | ||||
| mmu00982 | Drug metabolism | 1.85E-05 | 6.81E-04 | mmu04142 | Lysosome | 2.10E-09 | 5.42E-08 | ||||
| mmu04530 | Tight junction | 1.15E-04 | 3.53E-03 | mmu04612 | Antigen processing and presentation | 4.62E-09 | 9.93E-08 | ||||
| mmu04360 | Axon guidance | 1.58E-04 | 4.14E-03 | mmu04940 | Type I diabetes mellitus | 7.14E-09 | 1.32E-07 | ||||
| mmu05310 | Asthma | 2.00E-08 | 3.23E-07 | ||||||||
| mmu04062 | Chemokine signaling pathway | 7.04E-08 | 1.01E-06 | ||||||||
| mmu04514 | Cell adhesion molecules (CAMs) | 1.51E-07 | 1.94E-06 | ||||||||
| mmu04650 | Natural killer cell mediated cytotoxicity | 2.78E-07 | 3.26E-06 | ||||||||
| mmu04672 | Intestinal immune network for IgA production | 9.21E-07 | 9.90E-06 | ||||||||
| mmu05340 | Primary immunodeficiency | 1.10E-05 | 1.09E-04 | ||||||||
| mmu05320 | Autoimmune thyroid disease | 1.11E-05 | 1.03E-04 | ||||||||
| mmu05416 | Viral myocarditis | 1.25E-05 | 1.08E-04 | ||||||||
| mmu04660 | T cell receptor signaling pathway | 1.95E-05 | 1.57E-04 | ||||||||
| mmu04640 | Hematopoietic cell lineage | 1.55E-04 | 1.17E-03 | ||||||||
| mmu04666 | Fc gamma R-mediated phagocytosis | 5.51E-04 | 3.94E-03 | ||||||||
| mmu04610 | Complement and coagulation cascades | 8.61E-04 | 5.82E-03 | ||||||||
| mmu04621 | NOD-like receptor signaling pathway | 9.22E-04 | 5.93E-03 | ||||||||
| mmu04670 | Leukocyte transendothelial migration | 1.19E-03 | 7.32E-03 | ||||||||
| mmu04662 | B cell receptor signaling pathway | 1.43E-03 | 8.41E-03 | ||||||||
| Neighboring area | |||||||||||
| Pattern 1 | Pattern 2 | Pattern 3 | |||||||||
| KEGG ID | Name |
| FDR | ID | Name |
| FDR | ID | Name |
| FDR |
| mmu00982 | Drug metabolism | 8.90E-06 | 1.67E-03 | mmu04060 | Cytokine-cytokine receptor interaction | 3.39E-08 | 2.89E-06 | NA | NA | NA | NA |
| mmu05410 | Hypertrophic cardiomyopathy | 8.99E-05 | 8.41E-03 | mmu04062 | Chemokine signaling pathway | 1.36E-05 | 5.80E-04 | ||||
| mmu04260 | Cardiac muscle contraction | 1.36E-04 | 8.46E-03 | mmu04620 | Toll-like receptor signaling pathway | 2.68E-05 | 7.58E-04 | ||||
| mmu04010 | MAPK signaling pathway | 1.80E-04 | 8.44E-03 | ||||||||
| mmu05414 | Dilated cardiomyopathy | 1.93E-04 | 7.24E-03 | ||||||||
aFDR corrections were calculated using the Benjamini-Hochberg procedure
*p-values were calculated using Fischer’s test
Fig. 5Pathways altered by focal exposure to high-dose radiation. Pathways involved in Pattern 1, Pattern 2, Pattern 3, and all Patterns were analyzed via the Signaling Pathway Impact Analysis (SPIA) program in (a) focally-irradiated regions and (b) non-irradiated neighboring lung regions. The horizontal axis represents pathway over‐representation (PNDE), while the vertical axis indicates pathway perturbation (PPERT). The dotted horizontal and vertical lines represent the corrected thresholds (1 %) of significance (red color for Bonferroni and blue for FDR correction) for each axis value. The red and blue circles at the right of the oblique lines are significant pathways with KEGG ID after the correction (red line for 1 % and blue line for 5 % FDR correction) of the global p-values, PG. PG, representing pathway rank, was calculated from the combined probability of both PNDE and PPERT. The list of pathways for the red circles is shown in Table 3
Pathways significantly enriched (FDR <0.01) in lung focally exposed to high-dose radiation of 90 Gy using SPIA pathway analysis
| Focally irradiated area | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pattern 1 | Pattern 2 | Pattern 3 | All patterns | ||||||||||||
| KEGG ID | Name | PG* | FDRa | ID | Name | PG | FDR | ID | Name | PG | FDR | ID | Name | PG | FDR |
| 5414 | Dilated cardiomyopathy | 3.23E-07 | 4.20E-05 | 4060 | Cytokine-cytokine receptor interaction | 1.91E-23 | 2.21E-21 | 4115 | p53 signaling pathway | 7.45E-10 | 3.43E-08 | 4060 | Cytokine-cytokine receptor interaction | 1.81E-12 | 2.37E-10 |
| 5030 | Cocaine addiction | 1.68E-05 | 1.09E-03 | 5150 | Staphylococcus aureus infection | 1.91E-17 | 1.11E-15 | 5202 | Transcriptional misregulation in cancer | 3.70E-05 | 8.51E-04 | 5414 | Dilated cardiomyopathy | 4.36E-10 | 2.86E-08 |
| 4740 | Olfactory transduction | 4.54E-05 | 1.96E-03 | 5140 | Leishmaniasis | 5.15E-17 | 1.99E-15 | 5218 | Melanoma | 2.65E-04 | 3.21E-03 | 5150 | Staphylococcus aureus infection | 2.19E-07 | 9.56E-06 |
| 5412 | Arrhythmogenic right ventricular cardiomyopathy | 9.17E-05 | 2.98E-03 | 5322 | Systemic lupus erythematosus | 8.35E-16 | 2.42E-14 | 5166 | HTLV-I infection | 2.79E-04 | 3.21E-03 | 5322 | Systemic lupus erythematosus | 6.35E-07 | 2.08E-05 |
| 4380 | Osteoclast differentiation | 6.38E-15 | 1.48E-13 | 5214 | Glioma | 4.27E-04 | 3.92E-03 | 5152 | Tuberculosis | 9.41E-07 | 2.47E-05 | ||||
| 4062 | Chemokine signaling pathway | 7.48E-14 | 1.45E-12 | 5220 | Chronic myeloid leukemia | 6.01E-04 | 4.61E-03 | 4650 | Natural killer cell mediated cytotoxicity | 1.33E-06 | 2.87E-05 | ||||
| 5152 | Tuberculosis | 9.50E-14 | 1.57E-12 | 4612 | Antigen processing and presentation | 1.53E-06 | 2.87E-05 | ||||||||
| 4142 | Lysosome | 5.05E-13 | 7.33E-12 | 4062 | Chemokine signaling pathway | 2.85E-06 | 4.67E-05 | ||||||||
| 5323 | Rheumatoid arthritis | 1.07E-12 | 1.37E-11 | 5030 | Cocaine addiction | 2.49E-05 | 3.62E-04 | ||||||||
| 4612 | Antigen processing and presentation | 1.45E-12 | 1.69E-11 | 5140 | Leishmaniasis | 1.33E-04 | 1.73E-03 | ||||||||
| 4650 | Natural killer cell mediated cytotoxicity | 1.94E-10 | 2.04E-09 | 5031 | Amphetamine addiction | 2.48E-04 | 2.95E-03 | ||||||||
| 5310 | Asthma | 1.99E-09 | 1.92E-08 | 4020 | Calcium signaling pathway | 3.57E-04 | 3.60E-03 | ||||||||
| 5330 | Allograft rejection | 2.31E-09 | 2.07E-08 | 5412 | Arrhythmogenic right ventricular cardiomyopathy | 3.57E-04 | 3.60E-03 | ||||||||
| 5332 | Graft-versus-host disease | 2.58E-09 | 2.14E-08 | 4970 | Salivary secretion | 5.69E-04 | 5.32E-03 | ||||||||
| 4940 | Type I diabetes mellitus | 9.98E-09 | 7.72E-08 | 5323 | Rheumatoid arthritis | 6.43E-04 | 5.61E-03 | ||||||||
| 4672 | Intestinal immune network for IgA production | 2.96E-08 | 2.15E-07 | ||||||||||||
| 5162 | Measles | 6.19E-08 | 4.23E-07 | ||||||||||||
| 5164 | Influenza A | 1.14E-07 | 7.35E-07 | ||||||||||||
| 5168 | Herpes simplex infection | 1.68E-07 | 1.03E-06 | ||||||||||||
| 4660 | T cell receptor signaling pathway | 5.60E-07 | 3.25E-06 | ||||||||||||
| 4610 | Complement and coagulation cascades | 1.29E-06 | 7.11E-06 | ||||||||||||
| 5145 | Toxoplasmosis | 2.31E-06 | 1.22E-05 | ||||||||||||
| 4064 | NF-kappa B signaling pathway | 2.43E-06 | 1.22E-05 | ||||||||||||
| 5416 | Viral myocarditis | 4.68E-06 | 2.26E-05 | ||||||||||||
| 4662 | B cell receptor signaling pathway | 1.46E-05 | 6.77E-05 | ||||||||||||
| 5320 | Autoimmune thyroid disease | 2.37E-05 | 1.04E-04 | ||||||||||||
| 4666 | Fc gamma R-mediated phagocytosis | 2.41E-05 | 1.04E-04 | ||||||||||||
| 4620 | Toll-like receptor signaling pathway | 4.70E-05 | 1.95E-04 | ||||||||||||
| 4670 | Leukocyte transendothelial migration | 7.56E-05 | 3.02E-04 | ||||||||||||
| 5146 | Amoebiasis | 1.45E-04 | 5.62E-04 | ||||||||||||
| 5142 | Chagas disease | 1.58E-04 | 5.90E-04 | ||||||||||||
| 4630 | Jak-STAT signaling pathway | 1.71E-04 | 6.21E-04 | ||||||||||||
| 5202 | Transcriptional misregulation in cancer | 1.81E-04 | 6.36E-04 | ||||||||||||
| 4664 | Fc epsilon RI signaling pathway | 2.64E-04 | 9.01E-04 | ||||||||||||
| 5133 | Pertussis | 2.87E-04 | 9.50E-04 | ||||||||||||
| 5414 | Dilated cardiomyopathy | 1.13E-03 | 3.65E-03 | ||||||||||||
| 4623 | Cytosolic DNA-sensing pathway | 1.28E-03 | 4.03E-03 | ||||||||||||
| Neighboring area | |||||||||||||||
| Pattern 1 | Pattern 2 | Pattern 3 | All patterns | ||||||||||||
| ID | Name | PG | FDR | ID | Name | PG | FDR | ID | Name | PG | FDR | ID | Name | PG | FDR |
| NA | NA | NA | NA | 4060 | Cytokine-cytokine receptor interaction | 5.49E-10 | 4.72E-08 | 4115 | p53 signaling pathway | 5.40E-05 | 1.08E-03 | NA | NA | NA | NA |
| 4620 | Toll-like receptor signaling pathway | 4.06E-08 | 1.74E-06 | ||||||||||||
| 4062 | Chemokine signaling pathway | 2.81E-07 | 8.06E-06 | ||||||||||||
| 5152 | Tuberculosis | 1.75E-06 | 3.77E-05 | ||||||||||||
| 5323 | Rheumatoid arthritis | 3.60E-05 | 6.20E-04 | ||||||||||||
| 5164 | Influenza A | 5.34E-05 | 7.65E-04 | ||||||||||||
| 5162 | Measles | 6.80E-05 | 8.36E-04 | ||||||||||||
| 4064 | NF-kappa B signaling pathway | 1.35E-04 | 1.45E-03 | ||||||||||||
| 4660 | T cell receptor signaling pathway | 1.61E-04 | 1.54E-03 | ||||||||||||
| 4142 | Lysosome | 5.08E-04 | 4.37E-03 | ||||||||||||
| 4623 | Cytosolic DNA-sensing pathway | 6.69E-04 | 5.23E-03 | ||||||||||||
| 5160 | Hepatitis C | 7.90E-04 | 5.65E-03 | ||||||||||||
| 5168 | Herpes simplex infection | 9.39E-04 | 6.21E-03 | ||||||||||||
| 4622 | RIG-I-like receptor signaling pathway | 1.21E-03 | 7.17E-03 | ||||||||||||
| 5142 | Chagas disease | 1.25E-03 | 7.17E-03 | ||||||||||||
| 5332 | Graft-versus-host disease | 1.79E-03 | 9.66E-03 | ||||||||||||
aFDR value is calculated for PG value
*PG value indicates the global pathway significance p value, which combines the enrichment p values and the perturbation p values in regard to pathway topology with a random bootstrap iteration number of 3000
Fig. 6Pathway activities temporally changed by irradiation. Pathway activities were calculated by linearly combining gene expression levels and then were hierarchically clustered. The columns represent individual samples and the rows represent the pathways. The red and green colors reflect high and low activity levels, respectively, as indicated by the scale bar with arbitrary units. Pathways enriched from SPIA and simple enrichment analysis (FDR <0.01) are highlighted in black at the right panel with names
Fig. 7Interaction network of genes induced by focal exposure to high-dose radiation. By implementing Reactome FI application, an interaction network was constructed among 6681 and 6799 differentially expressed genes with at least two-fold variation in (a) focally-irradiated regions and in (b) non-irradiated neighboring lung regions, respectively. Both networks from (a) and (b) are composed of a total of 11 modules (as indicated from 0 to 10), each of which is differently colored. The representative GO term associated with each module was obtained from REVIGO program using module genes (FDR <0.01)